局部食管鳞状细胞癌诱导化疗后或放化疗后18F-FDG PET代谢反应的预后作用不同
这项回顾性研究分析了604例接受诱导化疗后放化疗(±手术)的局部食管鳞状细胞癌患者,比较诱导化疗后与放化疗后18F-FDG PET代谢反应的预后价值。放化疗后代谢反应是双模式与三模式治疗中强的独立预后因素;诱导化疗后代谢反应在双模式治疗中显著相关,在手术患者中不显著但初始计划手术者仍有预后意义。
要点
- 放化疗后代谢反应是局部食管鳞状细胞癌强的独立预后因素,支持用于风险分层。
- 双模式治疗中诱导化疗后完全代谢反应者生存最长(PFS 58.9个月;OS 90.8个月)。
- 手术患者中诱导化疗后代谢反应对生存无显著影响,但初始计划手术者仍有预后意义。
核心结论
- 放化疗后代谢反应是局部食管鳞状细胞癌的强预后标志物,支持其用于风险分层。
- 诱导化疗后早期代谢反应可能有助于治疗决策,尤其在计划手术的患者中。
研究设计与样本
- 回顾性研究纳入2006年至2018年在Asan Medical Center接受诱导化疗后放化疗(±手术)的604例局部食管鳞状细胞癌患者。
- 采用基于欧洲癌症研究与治疗组织标准并针对预后评估调整的代谢反应标准,分别评估诱导化疗后(放化疗前)和放化疗后的代谢反应。
主要发现
- 双模式治疗(根治性放化疗)中,诱导化疗后和放化疗后代谢反应均与无进展生存(PFS)和总生存(OS)显著相关(P < 0.001)。
- 诱导化疗后完全代谢反应者生存最长(PFS 58.9个月;OS 90.8个月),进展性代谢疾病者预后差(PFS 3.7个月;OS 7.0个月)。
- 手术(三模式治疗)患者中,诱导化疗后代谢反应对生存无显著影响;但在初始计划手术的患者中仍有预后意义。
- 放化疗后代谢反应在双模式治疗和三模式治疗中均为强的独立预后因素。
- 放化疗后弥漫性食管炎患者生存结局介于完全代谢反应与部分代谢反应组之间,提示不同的预后模式。
关键数值与推荐
- 代谢反应采用基于欧洲癌症研究与治疗组织标准并针对预后评估调整的标准评估。
- 双模式治疗中诱导化疗后完全代谢反应者PFS 58.9个月、OS 90.8个月;进展性代谢疾病者PFS 3.7个月、OS 7.0个月(P < 0.001)。
临床怎么用
- 放化疗后代谢反应可用于局部食管鳞状细胞癌的风险分层。
- 诱导化疗后早期代谢反应可能为治疗决策提供信息,尤其在计划手术的患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognostic significance of metabolic response by posttreatment 18F-FDG PET in esophageal squamous cell carcinoma (ESCC) treated with chemoradiotherapy remains unclear, particularly regarding metabolic response after induction chemotherapy versus after chemoradiotherapy. This study aimed to evaluate and compare their prognostic impact. Methods: This retrospective study analyzed 604 patients with localized ESCC who received induction chemotherapy followed by chemoradiotherapy, with or without surgery, at Asan Medical Center between 2006 and 2018. Metabolic responses after induction chemotherapy (before chemoradiotherapy) and after chemoradiotherapy were evaluated using European Organisation for Research and Treatment of Cancer-based criteria adapted for prognostic assessment. Results: In patients treated with definitive chemoradiotherapy (bimodality therapy), metabolic response after both induction chemotherapy and chemoradiotherapy was significantly associated with progression-free survival (PFS) and overall survival (OS). Complete metabolic response after induction chemotherapy correlated with the longest survival (PFS, 58.9 mo; OS, 90.8 mo), whereas progressive metabolic disease predicted poor prognosis (PFS, 3.7 mo; OS, 7.0 mo; P < 0.001). A similar pattern was observed for postchemoradiotherapy metabolic response. In patients who underwent surgery (trimodality therapy), metabolic response after induction chemotherapy did not significantly impact survival. However, in patients for whom surgery was initially planned, it remained prognostic, suggesting its prognostic relevance in the preoperative setting. Postchemoradiotherapy metabolic response was a strong independent prognostic factor in both bimodality therapy and trimodal therapy. Patients with diffuse esophagitis after chemoradiotherapy had intermediate survival outcomes, among complete metabolic response and partial metabolic response groups, indicating a distinct prognostic pattern. Conclusion: Postchemoradiotherapy metabolic response is a strong prognostic marker in localized ESCC, supporting its use for risk stratification. Early metabolic response after induction chemotherapy may also inform treatment decisions, particularly in surgery-intended patients.
引用
- Bang YH, Kim JH, Kim YH, et al. Distinct Prognostic Roles of 18F-FDG PET Metabolic Response Assessed After Induction Chemotherapy or Chemoradiotherapy in Localized Esophageal Squamous Cell Carcinoma. J Nucl Med. 2025. PMID: 40610231. doi:10.2967/jnumed.125.269775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。